

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: Prescient Therapeutics Limited</b>
<b>ABN: 56 006 569 106</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Dr Wayne A Millen
<b>Date of last notice</b>	29/10/2013
<b>Date that director ceased to be director</b>	28/11/2014

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
N/A

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest	
<b>Weighton Pty Ltd &lt;The Millen Family A/C&gt;</b> (a controlled entity of Dr Millen)	25,000,000 Fully paid ordinary shares 7,000,000 Unlisted Options exercisable @ \$0.005 each, expiring on 21 October 2017.

### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: Prescient Therapeutics Limited</b>
<b>ABN: 56 006 569 106</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Dr Roland Toder
<b>Date of last notice</b>	29/10/2013
<b>Date that director ceased to be director</b>	28/11/2014

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
N/A

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest	
<b>Akalpa Lifesciences Consulting Ltd</b> (a controlled entity of Dr Toder)	2,000,000 Unlisted Options exercisable @ \$0.005 each, expiring on 21 October 2017.

### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: Prescient Therapeutics Limited</b>
<b>ABN: 56 006 569 106</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Dr Brendan de Kauwe
<b>Date of last notice</b>	29/10/2013
<b>Date that director ceased to be director</b>	28/11/2014

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
N/A

+ See chapter 19 for defined terms.

## Appendix 3Z Final Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
<p>Note: Provide details of the circumstances giving rise to the relevant interest</p> <p><b>Dr Brendan de Kauwe &lt;Attollo Investment Trust A/C&gt;</b> (a controlled entity of Dr de Kauwe)</p> <p><b>Dekski SFT Pty Ltd &lt;Dekski Superfund A/C&gt;</b> (a controlled entity of Dr de Kauwe)</p>	<p>12,400,000 Fully paid ordinary shares</p> <p>5,000,000 Unlisted Options exercisable @ \$0.005 each, expiring on 21 October 2017.</p>

### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.